High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'

Autoimmunity Reviews

Volumn 11, Issue 8, 2012, Pages 577-580

  Pengo, Vittorio ^a   Ruiz Irastorza, Guillermo ^b   Denas, Gentian ^a   Andreoli, Laura ^c   Khamashta, Munther ^d   Tincani, Angela ^c  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSITY OF BRESCIA   (Italy)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Arterial thrombosis; Stroke; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; HUMAN; INTERNATIONAL NORMALIZED RATIO; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ARTERIES; CLINICAL PROTOCOLS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; THROMBOPLASTIN; THROMBOSIS;

EID: 84861482089     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.10.016     Document Type: Review

References (27)

1. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. Tincani A., Andreoli L., Casu C., et al. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010, 19:432-435.
3. Hughes G.R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983, 287(6399):1088-1089.
4. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46(4):1019-1027.
5. Cervera R., Khamashta M.A., Shoenfeld Y., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1,000 patients. Ann Rheum Dis 2009, 68(9):1428-1432.
6. Brey R.L., Muscal E., Chapman J. Antiphospholipid antibodies and the brain: a consensus report. Lupus 2011, 20(2):153-157.
7. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011, 20(2):206-218.
8. Lim W., Crowther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006, 295(9):1050-1057.
9. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57(8):1487-1495.
10. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995, 332:993-997.
11. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 2003, 349:1133-1138.
12. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848-853.
13. Levine S.R., Brey R.L., Tilley B.C., et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
14. Neville C., Rauch J., Kassis J., et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost 2009, 101:100-107.
15. Tan B.E., Thong B.Y., Shivananda S., et al. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 2009, 18:752-758.
16. Pengo V., Ruffatti A., Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8:237-242.
17. Okuma H., Kitagawa Y., Yasuda T., et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009, 7:15-18.
18. Tektonidou M.G., Laskari K., Panagiotakos D.B., et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
19. Brey R., Escalante E. Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998, 7(Suppl 2):S67-S74.
20. Rosove M.H., Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303-308.
21. Krnic-Barrie S., O'Connor C.R., Looney S.W., et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997, 157:2101-2108.
22. Robert A., Le Querrec A., Delahousse B., et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome-influence of the lupus anticoagulant on International Normalized Ratio, Groupe Méthodologie en Hémostase du Groupe d'Etudes sur l'Hémostases et la Thrombose. Thromb Haemost 1998, 80:99-103.
23. Greaves M., Cohen H., MacHin S.J., et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704-715.
24. Torn M., van der Meer F.J., Rosendaal F.R. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004, 164:668-673.
25. Albers G.W., Amarenco P., Easton J.D., et al. American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:630S-669S.
26. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347:969-974.
27. van Es R.F., Jonker J.J., Verheugt F.W., et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2study): a randomised controlled trial. Lancet 2002, 360:109-113.